Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.84USD
23 Jun 2017
Change (% chg)

$0.09 (+3.27%)
Prev Close
$2.75
Open
$2.81
Day's High
$2.84
Day's Low
$2.62
Volume
5,472,906
Avg. Vol
213,790
52-wk High
$2.85
52-wk Low
$0.68

Select another date:

Wed, Mar 15 2017

BRIEF-Catalyst Pharmaceuticals Q4 non-gaap loss per share $0.05 excluding items

* Catalyst pharmaceuticals announces fourth quarter and year-end 2016 financial results and provides corporate update

UPDATE 1-Catalyst Pharma's neuromuscular drug succeeds in study

March 15 Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Catalyst Pharma's neuromuscular drug succeeds in study

Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Catalyst Pharma's neuromuscular drug succeeds in study

March 15 Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

BRIEF-Catalyst Pharmaceuticals reports positive data from investigator-sponsored trial of firdapse

* Catalyst Pharmaceuticals announces positive data from investigator-sponsored trial of firdapse® in treating musk antibody positive myasthenia gravis

BRIEF-Biocept, Catalyst Pharma to provide liquid biopsy testing for small cell lung cancer

* Biocept and Catalyst Pharmaceuticals collaborate to provide liquid biopsy testing for small cell lung cancer to patients with Lambert Eaton Myasthenic Syndrome (LEMS)

Select another date:

More From Around the Web